Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VOLITIONRX LTDVNRX · Entity 8241 | Director · President and CEO | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VOLITIONRX LTD
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,115,547 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 486,000 · Balance 3,115,547 F1: On February 26, 2026, the reporting person was awarded 486,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy Concord International, Inc. | 1,007,718 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,007,718 F2: The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 34,076 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 34,076 |
Filing footnotes · ownership attribution and instrument terms
F1: On February 26, 2026, the reporting person was awarded 486,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date.
F2: The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Feb 27, 2026 21:32 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 486,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-001103 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,115,547 F1 · shares: On February 26, 2026, the reporting person was awarded 486,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 21:08 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 74,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-000370 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,629,547 F1 · shares: On March 17, 2025, the reporting person was awarded 249,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 74,700 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 24,900 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 174,300 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively. Read SEC document |
| November 17, 2025 Filed Nov 17, 2025 18:12 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 20,000 | $0.35 | $7,000.00 |
DisclosureSEC source: 0001477932-25-008380 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,554,847 Read SEC document |
| October 14, 2025 Filed Oct 15, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseWarrant (Right to Buy) · Derivative | 110,000 | $0.01 Strike: $0.60 | $1,100.00 |
DisclosureSEC source: 0001477932-25-007588 · form4.xml · derivative · entry 4 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2030-10-14 F1 · shares: The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer. The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant. Read SEC document |
| October 14, 2025 Filed Oct 15, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 110,000 | $0.51 | $56,100.00 |
DisclosureSEC source: 0001477932-25-007588 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,534,847 F1 · shares: The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer. The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 13:00 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 15,000 | $0.66 | $9,885.00 |
DisclosureSEC source: 0001477932-25-006725 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,624,847 Read SEC document |
| August 05, 2025 Filed Aug 6, 2025 13:00 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 78,125 | $0.64 | $50,000.00 |
DisclosureSEC source: 0001477932-25-005494 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,609,847 F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-005250 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,531,722 F1 · shares: The reporting person received 200,000 restricted stock units under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $2.50 per share of the Issuer's common stock for a minimum of thirty consecutive trading days prior to July 24, 2028, which date shall be no earlier than July 24, 2026, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 12:27 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 12,500 | $0.59 | $7,372.50 |
DisclosureSEC source: 0001477932-25-004603 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,331,722 Read SEC document |
| May 19, 2025 Filed May 19, 2025 16:43 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 20,000 | $0.44 | $8,730.00 |
DisclosureSEC source: 0001477932-25-003959 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,319,222 Read SEC document |
| March 26, 2025 Filed Mar 27, 2025 12:13 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 181,818 | $0.55 | $99,999.90 |
DisclosureSEC source: 0001477932-25-002073 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,299,222 F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0001477932-25-000614 · form4.xml · derivative · entry 2 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-11 F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0001477932-25-000614 · form4.xml · derivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-02-11 F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 139,811 | $0.57 | $79,999.85 |
DisclosureSEC source: 0001477932-24-007969 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,117,404 F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 20:03 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 103,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005502 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,977,593 F1 · shares: On September 1, 2024, the reporting person was awarded 103,243 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 34,415 units, 34,414 units, and 34,414 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 29,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005024 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,874,350 F1 · shares: On Sept 28, 2023, the reporting person was awarded 118,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to Dec 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 29,500 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 9,833 units, 9,833 units, and 9,834 units on each of Sept 28, 2024, 2025 and 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in Jan 2024, the rights with respect to 50,150 RSUs subject to the award previously vested and remain subject to time-based vesting. The rights with respect to the remaining 38,350 RSUs did not vest and were cancelled on August 15, 2024. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 90,182 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-003488 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,844,850 F1 · shares: On June 1, 2024, the reporting person was awarded 90,182 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 30,061 units, 30,061 units, and 30,060 units on each of June 1, 2024, July 1, 2024 and August 1, 2024, respectively, are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 50,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-000401 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,754,668 F1 · shares: On September 28, 2023, the reporting person was awarded 118,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 50,150 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 16,717 units, 16,717 units, and 16,716 units on each of September 28, 2024, September 28, 2025 and September 28, 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 13:51 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 10,000 | $0.67 | $6,700.00 |
DisclosureSEC source: 0001477932-23-009055 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,704,518 Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 20:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-007778 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,694,518 F1 · shares: On October 19, 2023, the reporting person was awarded 200,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $5.00 per share of the Issuer's common stock for a minimum of thirty consecutive trading days prior to October 19, 2026, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| August 16, 2023 Filed Aug 16, 2023 16:28 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 10,000 | $1.22 | $12,200.00 |
DisclosureSEC source: 0001477932-23-006213 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,494,518 Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 40,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005117 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,484,518 F1 · shares: On October 4, 2022, the reporting person was awarded 89,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 40,050 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 13,350 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in October 2022 and January 2023 respectively, the rights with respect to 15,575 RSUs and 33,375 RSUs subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 33,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000262 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,444,468 F1 · shares: On October 4, 2022, the reporting person was awarded 89,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 33,375 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 11,125 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 15,575 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 20:08 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 15,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007704 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,411,093 F1 · shares: On October 4, 2022, the reporting person was awarded 89,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,575 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three installments of 5,192 units, 5,192 units, and 5,191 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007487 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,395,518 F1 · shares: On October 4, 2022, the reporting person was awarded 200,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $5.00 per share of the Issuer's common stock for a minimum of ten consecutive trading days prior to October 4, 2025, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| August 30, 2022 Filed Aug 30, 2022 15:19 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 3,500 | $1.61 | $5,635.00 |
DisclosureSEC source: 0001477932-22-006512 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,195,518 Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:04 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 59,466 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001477932-22-004662 · form4.xml · derivative · entry 4 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,486 Underlying: Common Stock · 59,466 shares Expires 2031-08-03 F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 59,466 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 29,733 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 32,020 shares subject to the award previously vested and remain subject to time-based vesting. F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 59,466 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 29,733 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 32,020 shares subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:04 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 32,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-004662 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,192,018 F1 · shares: On August 3, 2021, the reporting person was awarded 49,645 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 32,270 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 16,136 units and 16,134 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 17,375 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 32,020 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001477932-22-002188 · form4.xml · derivative · entry 4 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,020 Underlying: Common Stock · 32,020 shares Expires 2031-08-03 F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 32,020 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 16,010 shares on each of August 3, 2022 and August 3, 2023, respectively. F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 32,020 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 16,010 shares on each of August 3, 2022 and August 3, 2023, respectively. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 17,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-002188 · form4.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159,748 F1 · shares: On August 3, 2021, the reporting person was awarded 49,645 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,375 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 8,687 units and 8,688 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 85,000 | Not disclosed Strike: $3.60 | Not disclosed |
DisclosureSEC source: 0001477932-21-009119 · form4.xml · derivative · entry 2 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2030-04-13 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 85,000 | Not disclosed Strike: $3.60 | Not disclosed |
DisclosureSEC source: 0001477932-21-009119 · form4.xml · derivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires 2026-04-13 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007870 · form4.xml · derivative · entry 6 Reynolds Cameron John · CIK 0001340610 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-01-23 F3 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). F3 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007870 · form4.xml · derivative · entry 5 Reynolds Cameron John · CIK 0001340610 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2024-01-23 F3 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). F3 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007870 · form4.xml · derivative · entry 4 Reynolds Cameron John · CIK 0001340610 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-03-30 F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant). F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007870 · form4.xml · derivative · entry 3 Reynolds Cameron John · CIK 0001340610 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2023-03-30 F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant). F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007870 · form4.xml · derivative · entry 2 Reynolds Cameron John · CIK 0001340610 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2026-04-15 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007870 · form4.xml · derivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2022-04-15 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant). Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 20:38 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 55,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001078782-21-000675 · primary_doc.xml · derivative · entry 2 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2025-07-23 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant). Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 20:38 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001078782-21-000675 · primary_doc.xml · derivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2021-07-23 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant). Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:41 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001078782-20-000560 · primary_doc.xml · derivative · entry 8 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2020-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:41 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001078782-20-000560 · primary_doc.xml · derivative · entry 7 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2020-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:41 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 43,627 | $3.95 | $172,326.65 |
DisclosureSEC source: 0001078782-20-000560 · primary_doc.xml · nonDerivative · entry 4 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,142,373 F1 · shares: Represents the aggregate number of shares of Common Stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise and to satisfy the tax withholding obligations of the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:41 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionCommon Stock | 50,000 | $3.00 | $150,000.00 |
DisclosureSEC source: 0001078782-20-000560 · primary_doc.xml · nonDerivative · entry 3 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,186,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:41 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 40,273 | $3.95 | $159,078.35 |
DisclosureSEC source: 0001078782-20-000560 · primary_doc.xml · nonDerivative · entry 2 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,136,000 F1 · shares: Represents the aggregate number of shares of Common Stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise and to satisfy the tax withholding obligations of the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:41 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionCommon Stock | 50,000 | $2.50 | $125,000.00 |
DisclosureSEC source: 0001078782-20-000560 · primary_doc.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,176,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2020 Filed May 22, 2020 20:27 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 4,000 | $2.75 | $11,000.00 |
DisclosureSEC source: 0001078782-20-000367 · primary_doc.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,126,273 F1 · shares: The shares were purchased by the reporting person in connection with an underwritten public offering by the Issuer. The offering closed on May 22, 2020. The reported sale price reflects the price at which the reporting person purchased the shares from the underwriter. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:53 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001078782-20-000261 · primary_doc.xml · derivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2026-04-13 F1 · derivative.exercise_date: A total of 85,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant. Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 15:22 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 1,100 | $4.24 | $4,664.00 |
DisclosureSEC source: 0001078782-19-000892 · primary_doc.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,122,273 Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:21 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001078782-19-000126 · primary_doc.xml · derivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-02-11 F1 · derivative.exercise_date: A total of 50,000 Options were granted on February 11, 2019 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.